Takeda Financial Statements From 2010 to 2025

TAK Stock  USD 14.36  0.28  1.99%   
Takeda Pharmaceutical financial statements provide useful quarterly and yearly information to potential Takeda Pharmaceutical Co investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Takeda Pharmaceutical financial statements helps investors assess Takeda Pharmaceutical's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Takeda Pharmaceutical's valuation are summarized below:
Takeda Pharmaceutical Co does not presently have any fundamental trend indicators for analysis.
Check Takeda Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Takeda Pharmaceutical's main balance sheet or income statement drivers, such as , as well as many indicators such as . Takeda financial statements analysis is a perfect complement when working with Takeda Pharmaceutical Valuation or Volatility modules.
  
Check out the analysis of Takeda Pharmaceutical Correlation against competitors.

Takeda Pharmaceutical Co Company Return On Equity Analysis

Takeda Pharmaceutical's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Takeda Pharmaceutical Return On Equity

    
  0.0294  
Most of Takeda Pharmaceutical's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Takeda Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Based on the latest financial disclosure, Takeda Pharmaceutical Co has a Return On Equity of 0.0294. This is 100.12% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The return on equity for all United States stocks is 109.48% lower than that of the firm.

Takeda Pharmaceutical Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Takeda Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Takeda Pharmaceutical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Takeda Pharmaceutical competition to find correlations between indicators driving Takeda Pharmaceutical's intrinsic value. More Info.
Takeda Pharmaceutical Co is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers reporting about  0.85  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Takeda Pharmaceutical Co is roughly  1.17 . Comparative valuation analysis is a catch-all technique that is used if you cannot value Takeda Pharmaceutical by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

About Takeda Pharmaceutical Financial Statements

Takeda Pharmaceutical investors utilize fundamental indicators, such as revenue or net income, to predict how Takeda Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan. Takeda Pharmaceutical operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 47347 people.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Takeda Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Takeda Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Takeda Pharmaceutical Co Stock. Highlighted below are key reports to facilitate an investment decision about Takeda Pharmaceutical Co Stock:
Check out the analysis of Takeda Pharmaceutical Correlation against competitors.
You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.